Associated tags: Immune system, Vaccine, Viral, Pharmaceutical industry, Gritstone, Gritstone bio, Infection, COVID-19
Locations: GILEAD, SOUTH AFRICA, BOSTON, MA, SWITZERLAND, BRITISH COLUMBIA, CAMBRIDGE, MASS., BARDA, KRAS, EMERYVILLE, CA, US, NEW YORK, NY, CHICAGO, LOS ANGELES, TEL AVIV, PARIS, LONDON
PFS,
FDA,
SLATE,
Administration,
Research,
HLA,
Death,
CRC,
Doctor of Philosophy,
National Cancer Institute,
Vaccine,
Development,
IND,
Melinda French Gates,
NCI,
AACR,
Food,
ESCMID,
Roche,
Messenger,
HIV,
Therapy,
CEPI,
Neoplasm,
Infection,
Gritstone bio,
DNA,
GMP,
Clinical trial,
Progression-free survival,
Human services,
Immunotherapy,
Spark Therapeutics,
MD,
Disease,
Patient,
Acquisition,
VAF,
PD,
COVID-19,
Pharmaceutical industry -- Gritstone to host conference call today at 4:30pm ET --
Key Points:
- In April 2024, Gritstone appointed Stephen Webster to its Board of Directors.
- Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
- Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
- In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024.
EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.
Key Points:
- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024.
- The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.
- While not required, it is recommended you join five minutes prior to the event's start.
- An archived replay will be accessible at https://ir.gritstonebio.com/investors/events for 30 days following the event.
Retrieved on:
Wednesday, April 24, 2024
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).
Key Points:
- NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).
- Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- The investigation concerns whether Gritstone and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).
Key Points:
- NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).
- Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- The investigation concerns whether Gritstone and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
SLATE,
Mutation,
Safety,
HLA,
Trial of the century,
National Cancer Institute,
Vaccine,
Gritstone bio,
Human,
Antigen presentation,
BRAF,
Oncogene,
Patient,
TP53,
NCI,
CTNNB1,
Pharmaceutical industry EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a “pure” KRAS-directed candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study and is currently being evaluated in a novel cell therapy-vaccine combination study run by Steven A. Rosenberg of the National Cancer Institute (NCT06253520).
Key Points:
- "Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology.
- Neoantigens were identified using Gritstone bio’s proprietary neoantigen prediction platform, EDGETM, and selected based on shared mutation and matched HLA frequencies in patient populations with solid tumors.
- These data led to the development of SLATE-KRAS, a vaccine focused on KRAS-derived neoantigens that subsequently was evaluated in the Phase 2 portion of the clinical study.
- Initial Phase 2 data suggesting an increased vaccine induced T cell response were presented in September 2022 ( press release ).
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).
Key Points:
- NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gritstone bio, Inc. (“Gritstone” or the “Company”) (NASDAQ: GRTS).
- Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- The investigation concerns whether Gritstone and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
AP,
Infection,
HIV,
Nature Biotechnology,
Epitope,
Cancer,
SARS-CoV-2,
Gritstone bio,
HLA,
AACR,
Immunity,
EDGE,
Poster,
Vaccine EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
Key Points:
- The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
- It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
- “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
- The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences.
Key Points:
- EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences.
- Select events (marked by *) will be webcasted live and webcast details will be available on the ‘Events’ page of Gritstone bio’s website: https://ir.gritstonebio.com/investors/events .
- Archived replays will be accessible for 30 days following each event.
- Presentation Title: Clinical Trial Results with a Personalised Neoantigen Vaccine in a Cold Tumour—Can We Bring the Heat?
Vanderbilt Avenue,
TD Securities,
Exercise,
Form,
Telephone,
Sale,
Attention,
Gritstone bio,
Form S-3,
Vaccine,
Equity capital markets,
Evercore,
Security (finance) EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
Key Points:
- EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
- The accompanying common warrants will be immediately exercisable for shares of common stock or pre-funded warrants in lieu thereof, and will expire on the twelve-month anniversary of the date of issuance.
- All of the shares of common stock, accompanying common warrants and pre-funded warrants are being offered by Gritstone bio.
- The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.
Vanderbilt Avenue,
TD Securities,
Form,
Telephone,
Sale,
Attention,
Gritstone bio,
Form S-3,
Vaccine,
Equity capital markets,
Evercore,
Security (finance) All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.
Key Points:
- All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.
- The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- TD Cowen and Evercore ISI are acting as the joint book-running managers for the proposed offering.
- The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.
